

Colleagues,

Please find below the National Notifiable Diseases Surveillance System (NNDSS) Modernization Initiative (NMI) Technical Assistance (TA) Coordination Team Update for July 3, 2015. These e-mail updates are a collaboration among the Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), and the Association of Public Health Laboratories (APHL) and will be sent biweekly in an effort to keep reporting jurisdictions and other partners and stakeholders updated on the progress of NMI.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.

NNDSS Modernization Initiative Biweekly Update

July 3, 2015

NMI Overall Updates

- Staff members from all three NMI partners—CDC, CSTE, and APHL—shared NMI accomplishments and plans during several NMI-related sessions at the CSTE Annual Conference, held in Boston, Massachusetts, last week from 6/14/15 to 6/18/15.
 - The sessions were well attended, and participants expressed their support for the overall NMI effort and their hope that MMGs for all notifiable conditions would be developed as quickly as possible.

Message Mapping Guide Development Updates

- **Message Mapping Guide (MMG) Status Updates:**
 - **Arboviral and Varicella MMGs**
 - These MMGs are in the “Requirements Analysis” phase of development, which is a step that precedes the actual construction of the draft MMGs.
 - **Mumps and Pertussis MMGs ([Stage 1—Draft Phase](#)):**
 - The second external review period for the restructured Mumps and Pertussis MMGs closed on 5/22/15.
 - The MMG Development Team has addressed the 50 comments received from four states (Washington, California, Virginia, and Minnesota). The team met with the CDC programs on 6/26/15 to discuss vocabulary issues and clarifications that are needed for the MMGs. After these issues have been resolved, the team will share the revised MMGs with the CDC program for their review.
 - **Congenital Syphilis and STD MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
 - The MMG Development Team posted pilot test-ready versions of the STD and Congenital Syphilis MMGs and their artifacts to the Draft MMG Web Site.
 - **Generic v2 and Hepatitis MMGs ([Stage II—Pilot Test-ready Draft Phase](#))**
 - The MMG Development Team posted pilot test-ready versions of the Generic v2 and Hepatitis MMGs and their artifacts to the Draft MMG Web Site.
 - No guides are in [Stage III—Final MMG Phase](#) at this time.

Message Validation, Processing, and Provisioning System Updates

- The Message Validation, Processing, and Provisioning System (MVPS) developer delivered the message processing functions code for Generic v2, STD, and Hepatitis to CDC on 6/5/15.
 - CDC installed the code on 6/11/15 and performed technical acceptance testing of the Message Evaluation and Testing Service (METS), the MVPS Dashboard, and message processing functions from 6/11/15 to 6/19/15.
 - CDC sent a list of defects found to the MVPS developer on 6/19/15 in anticipation of the developer delivering code that incorporates the defect resolutions on 7/2/15.
- The MVPS Team continues to work on finalizing the data provisioning requirements and data dictionary mapping for Generic v2, Hepatitis, and STD in conjunction with the Surveillance Operations Team and the Message and Vocabulary Team.
 - The MVPS Team delivered the Generic v2 requirements to the MVPS developer on 6/4/15. The team is now focused on completing the Hepatitis and STD data provisioning requirements in that order.
 - The MVPS Team met with the CDC programs to discuss the Generic v2, Hepatitis, and STD data dictionary and data provisioning design and approach on 6/23/15.
 - The team's goal is to submit data provisioning requirements to the MVPS developer before the end of July 2015, with a target of completing Hepatitis requirements on 7/21/15 and STD requirements by 7/30/15. This time frame will allow the MVPS developer to clarify any issues prior to starting their development in August 2015.
- The MVPS Team received the authority to operate (ATO) from the CDC Office of the Chief Information Security Officer (OCISO) for the multi-server environment on 6/6/15.
 - The MVPS Team has prepared for the move ("cutover") to production to the multi-server environment and has staged several dry runs.
 - To complete the cutover to production, the team is awaiting delivery of the SQL Server Integration Services (SSIS) package, anticipated to be completed by the MVPS developer the week of 7/6/15.
 - The MVPS Team will then submit a change request (CR) to OCISO to update the ATO to incorporate the MVPS security code and dashboard enhancements as part of the multi-server environment.
 - The team will submit the CR as soon as all defect resolutions from technical acceptance testing are received from the MVPS developer, anticipated to be on 7/2/15.
 - The typical cycle time for OCISO to approve a CR is 30 days.
 - Once the multi-server code is promoted to production, the MVPS dashboard and message processing code will be moved to the test environment to prepare for user acceptance testing (UAT), targeted for 7/10/15.
- The MVPS Team installed and tested the updated METS code the week of 6/11/15 in the test environment. The MVPS Team promoted METS to the production environment on 6/23/15 to make the code available to jurisdictions to support their independent validation testing of Hepatitis, STD, and Generic v2 messages.
- The MVPS Team is finalizing Secure Access Management Services (SAMS) training documentation in preparation to train pilot jurisdictions on SAMS, expected to occur on 7/9/15. In addition to the SAMS training, the NMI pilot jurisdictions supporting UAT will also receive UAT training and MVPS Dashboard training on that date.

Technical Assistance Updates

- On 6/18/15, Lesliann Helmus, Jason Hall, and Michele Hoover spoke to the MAVEN User Group meeting held after the CSTE Annual Conference in Boston.
 - An overview of NMI technical assistance (TA) activities was discussed as an option for jurisdictions using MAVEN surveillance systems.
 - MAVEN and CDC will continue to work together to find solutions that are cost efficient and reusable for NMI jurisdictions to send case notification messages.
- **Update on Jurisdiction Implementation:** Note that all pilot jurisdictions are working on both Hepatitis and STD at the same time and are using the test messages and scenarios developed by CDC. Additional test messages may be developed by the jurisdictions.
 - **California:**
 - The APHL TA Team and the technical team from California continue to work on implementing the messaging plan, building the data extract, and customizing the Rhapsody route for California.
 - **Minnesota:**
 - Minnesota has completed the gap analysis for Hepatitis and is in progress for STD.
 - The state is currently implementing the designed technical solution.
 - **Oregon**
 - Oregon has completed the gap analysis for Hepatitis and STD and installed the Rhapsody route and validator. The APHL TA Team is reviewing and providing feedback on test messages as they are created.
 - Initial test messages for Hepatitis and STDs have been validated in METS and feedback provided to the technical team at Oregon for review.
 - **Michigan:**
 - Michigan has completed the full suite of test messages for Hepatitis and STD in preparation for internal validation. The APHL TA Team is reviewing and providing feedback on test messages as they are created.
 - Initial test messages have been validated in METS and feedback provided to the technical team at Michigan for review.
 - **Florida:**
 - Florida is completing the gap analysis for Hepatitis and STD.
 - Florida will pilot the Mirth Channel created by the APHL TA Team. The Mirth validator has been installed and tested in the Florida system.
- CSTE will work with all of the pilot jurisdictions to evaluate the NMI TA efforts.
- Reminder about MMG status:
 - MMGs in Stages I and II are considered draft and may be revised until the time they are finalized.
 - Those jurisdictions selected for pilot testing of the test-ready versions (Stage II) of the MMGs should wait until contacted by the NMI TA Team before using the test-ready MMGs, before implementing surveillance information system changes, and before submitting test messages to CDC.
 - All other jurisdictions should not plan to submit data to CDC or implement MMG-based updates to their surveillance information systems until the final MMGs (Stage III) have been posted.
- For more information about technical assistance:

- Please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>.
- For pilot jurisdictions: If you have questions specific to NMI TA, please contact Laura Carlton, APHL, at laura.carlton@aphl.org.
- For non-pilot jurisdictions: If you have questions or would like to request TA through the Epidemiology and Laboratory Capacity for Infectious Diseases (ELC) Cooperative Agreement, please email edx@cdc.gov.

For more information on NMI, please see the NMI FAQs at <http://www.cdc.gov/nmi/faq.html>. If you have questions not answered in the FAQs, please send them to edx@cdc.gov.